Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 11/20 | 0.74 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | APEX1 | P27695 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12233680 | 1.00 | SLC18A3 (0.74) | SLC18A3CYP2D6TSHRSMN1; SMN2CYP1A2 | |
| SCHEMBL8989794 | 1.00 | SLC18A3 (0.74) | SLC18A3CYP2D6TSHRSMN1; SMN2CYP1A2 | |
| SCHEMBL908579 | 1.00 | SLC18A3 (0.74) | SLC18A3CYP2D6TSHRSMN1; SMN2CYP1A2 | |
| SCHEMBL29075879 | 1.00 | SLC18A3 (0.74) | SLC18A3CYP2D6TSHRSMN1; SMN2CYP1A2 | |
| SCHEMBL17286254 | 1.00 | SLC18A3 (0.74) | SLC18A3CYP2D6TSHRSMN1; SMN2CYP1A2 | |
| SCHEMBL14367947 | 1.00 | SLC18A3 (0.74) | SLC18A3CYP2D6TSHRSMN1; SMN2CYP1A2 | |
| SCHEMBL25305403 | 1.00 | SLC18A3 (0.74) | SLC18A3CYP2D6TSHRSMN1; SMN2CYP1A2 | |
| SCHEMBL4488180 | 1.00 | SLC18A3 (0.74) | SLC18A3CYP2D6TSHRSMN1; SMN2CYP1A2 | |
| SCHEMBL11346322 | 0.97 | SLC18A3 (0.72) | SLC18A3CYP2D6TSHRSMN1; SMN2CYP1A2 | |
| SCHEMBL6597975 | 0.97 | SLC18A3 (0.72) | SLC18A3CYP2D6TSHRSMN1; SMN2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362003-B2 | 3-aminopyrrolidine derivatives as modulators of chemokine receptors | INCYTE CORPORATION (US) | 2013-01-29 | — | — | US | disclosed |
| US-20090005576-A1 | Production Method of Optically Active Cyclohexane Ether Compounds | ASTELLAS PHARMA INC. (JP) | 2009-01-01 | — | — | US | disclosed |
| US-20090005576-A1 | Production Method of Optically Active Cyclohexane Ether Compounds | ASTELLAS PHARMA INC. (JP) | 2009-01-01 | — | — | US | disclosed |
| US-6884893-B1 | Method for selectively dissociating cyclic carboxylic acid anhydrides | MERCK PATENT GMBH (DE) | 2005-04-26 | — | — | US | disclosed |
| EP-0905132-B1 | Benzothiophenes | LILLY CO ELI (US) | 2004-08-04 | — | — | EP | disclosed |
| US-6060488-A | ANTICARCINOGENIC AGENTS; POSTMENOPAUSAL CANCER OF BREASTS, UTERUS, CERVIX | ELI LILLY AND COMPANY (US) | 2000-05-09 | — | — | US | disclosed |
| WO-1999015521-A1 | BENZOTHIOPHENES | ELI LILLY AND COMPANY (US) | 1999-04-01 | — | — | WO | disclosed |
| EP-0905132-A1 | Benzothiophenes | ELI LILLY AND COMPANY (US) | 1999-03-31 | — | — | EP | disclosed |
| EP-0863755-A4 | ANTITHROMBOTIC DIAMINES | LILLY CO ELI (US) | 1999-01-20 | — | — | EP | disclosed |
| EP-0863755-A1 | ANTITHROMBOTIC DIAMINES | ELI LILLY AND COMPANY (US) | 1998-09-16 | — | — | EP | disclosed |
| WO-1997025033-A1 | ANTITHROMBOTIC DIAMINES | ELI LILLY AND COMPANY (US) | 1997-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005576-A1 | Production Method of Optically Active Cyclohexane Ether Compounds | DHPS, CYP8B1, CYP51A1 | SLC18A3 3557/4885CYP2D6 43/4885TSHR 2487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.